The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation

Chronic Kidney Diseases Clinical Trial

— WAVE-Global  

Official title:

The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Multi-Center, Prospective, Post-Market, Confirmatory, Interventional, Investigation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04626427
• Other study ID #: BDPI-19-005
• Status: Terminated
• Phase: N/A
• Start date: December 22, 2020
• Est. completion date: June 15, 2022

Study information

• Verified date: October 2021
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in patients who require a vascular access for hemodialysis (HD).

Description:

The purpose of this clinical investigation is to provide clinical evidence to further demonstrate reasonable assurance of safety and effectiveness of the WavelinQ™ EndoAVF System when used for endovascular arteriovenous fistula (endoAVF) creations. Treated participants will be followed for 24-months post index procedure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: June 15, 2022
• Est. primary completion date: June 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

The participant must:

1. Be able to comprehend, voluntarily sign and date the informed consent form (ICF) prior to collection of clinical investigation data or performance of clinical investigation procedures (or where allowable the participant's legally authorized representative (LAR) on behalf of the participant).

2. Be able to and willing to comply with the CIP requirements, including clinical follow-up.

3. Be male or non-pregnant female = 18 years of age with an expected lifespan sufficient (= 24 months) to allow for completion of all clinical investigation procedures.

4. Have established, non-reversible kidney failure, who are currently on HD at screening or are in need of a vascular access for HD as determined by the referring clinician.

5. Target treatment vein diameter(s) for AVF creation = 2.0 mm as measured via DUS or angiography.

6. A target treatment artery diameter = 2.0 mm as measured via DUS or angiography.

7. Adequate collateral circulation to the hand, in the opinion of the Principal Investigator (PI) (or authorized designee).

8. At least one superficial outflow vein diameter = 2.5 mm as measured via DUS or angiography that is in communication with the target creation site via a proximal forearm perforating vein.

Exclusion Criteria:

The participant must not have:

1. Active or nontreated hypercoagulable state.

2. Known bleeding diathesis.

3. Insufficient cardiac output to support the maturation and use of an AVF in the opinion of the PI (or authorized designee).

4. Known history of or current active intravenous drug abuse.

5. A "planned" major surgical procedure within 6 months following index procedure or major surgery, in the opinion of the PI (or authorized designee), within 30 days prior to index procedure.

6. Known allergy or hypersensitivity to contrast media which cannot be adequately treated with pre-medication.

7. Known adverse effects to sedation and / or anesthesia which cannot be adequately treated with pre-medication.

8. Evidence of active infection on the day of the index procedure (temperature of = 38.0° Celsius and / or White Blood Cell (WBC) Count of = 12,000 cells / µL, if collected).

9. Another medical condition, which, in the opinion of the PI (or authorized designee), may cause him / her to be non-compliant with the CIP, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of clinical investigation procedures and follow-up.

10. Current participation in an investigational drug or device clinical investigation that has not completed the clinical investigation treatment or that clinically interferes with the clinical investigation endpoints. Note: Investigations requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational.

11. Central venous stenosis or central vein narrowing = 50% based on imaging, or any degree of central venous stenosis with accompanying signs or symptoms, on the same side as the planned AVF creation.

12. The absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via DUS or angiography.

13. Occlusion or stenosis = 50%, or any degree of stenosis with accompanying signs or symptoms of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via DUS or angiography and as clinically determined by PI (or authorized designee).

14. Significantly compromised venous or arterial architecture (e.g. severe vessel calcification) or flow in the treatment arm as determined by the PI (or authorized designee) and DUS or angiography.

15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the PI (or authorized designee).

Related Conditions & MeSH terms

• Arteriovenous Fistula
• AV Fistula
• Chronic Kidney Diseases
• End Stage Kidney Disease
• Fistula
• Fistulas Arteriovenous
• Kidney Disease, Chronic
• Kidney Diseases
• Kidney Failure
• Kidney Failure, Chronic
• Kidney Insufficiency
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Device:
• WavelinQ™ EndoAVF System
AVF endovascular creations using the WavelinQ™ EndoAVF System

Locations

Country	Name	City	State
Belgium	Imelda Hospital Bonheiden	Bonheiden
Greece	University Hospital of Patras "Panagia I Voitheia"	Río
Switzerland	Kantonsspital Winterthur	Winterthur

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Countries where clinical trial is conducted

Belgium,  Greece,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Device and Procedure Related Serious Adverse Events (SAEs)	The proportion of participants with freedom from Clinical Events Committee (CEC) adjudicated device- or procedure-related SAEs.	30 days
Primary	Effectiveness: Number of Post Creation Interventions	The number of interventions post creation to facilitate and / or maintain AVF use (facilitation interventions and / or maintenance interventions).	6-months
Secondary	Device and Procedure Related SAEs	The proportion of participants with freedom from CEC adjudicated device- or procedure-related SAEs.	6- and 24-months
Secondary	Physiological Maturation	The proportion of participants with AVFs that meet the clinical investigation plan (CIP) definition of physiological maturation as measured by duplex ultrasound (DUS).	6-weeks
Secondary	Cannulation Success	The interval of time between HD arteriovenous (AV) access creation to first successful use for HD and proportion of participants with successful first use for HD as defined in the CIP.	6-months
Secondary	Cumulative Functional Patency	The time from first successful HD AV access use for HD using 2-needle cannulation to access abandonment, when the access reaches an access censoring event as specified a priori in the CIP, or analysis timepoint / clinical investigation end.	12-months